Global Cell Therapy (Autologous, Allogeneic) Markets to 2027 – Yahoo Finance

Dublin, March 10, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Research, Commercialized, Musculoskeletal Disorders), by Therapy Type (Autologous, Allogeneic), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4%, over the forecast period.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Moreover, rapid advances in stem cell research hold the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. These factors have boosted revenue growth for the market.

Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market. Furthermore, LAVIV (Azficel-T), manufactured and commercialized by Fibrocell Technologies, witnessed revenue wind-down in the past years. Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.

The introduction of proprietary cell lines is recognized as the primary means by which a single cell can be exploited for the production of a robust portfolio of candidates. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.

For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs. Increase in the number of collaborations between entities for product commercialization is anticipated to accelerate market revenue to a major extent in the coming years.

In Asia-Pacific, the market is anticipated to witness significant growth over the forecast period. This is attributed to rising awareness cellular therapies among patients and healthcare entities in chronic disease management. In addition, availability of therapeutic treatment at lower prices is also driving the regional market. Japan is likely to witness fast growth over the forecast period attributed to increasing research activities on regenerative medicine.

Further key findings from the report suggest:

Key Topics Covered

Chapter 1 Executive Summary

Chapter 2 Research Methodology

Chapter 3 Cell Therapy Market Variables, Trends & Scope3.1 Market Segmentation & Scope3.1.1 Market driver analysis3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies3.1.1.2 Rising adoption of regenerative medicine3.1.1.3 Introduction of novel platforms and technologies3.1.2 Market restraint analysis3.1.2.1 Ethical concerns related to stem cell research3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy3.1.2.2.1 Manufacturing issues3.1.2.2.2 Genetic instability3.1.2.2.3 Stem cell culture condition3.1.2.2.4 Stem cell distribution after transplant3.1.2.2.5 Immunological rejection3.1.2.2.6 Challenges associated with allogeneic mode of transplantation3.2 Penetration & Growth Prospect Mapping For Therapy Type, 20193.3 Cell Therapy Market (Stem & Non-stem Cells)-Swot Analysis, by Factor (Political & Legal, Economic and Technological)3.4 Industry Analysis - Porter's3.5 Cell Therapy Market (Stem & Non-stem Cells)-Regulatory Landscape

Chapter 4 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Use-type Estimates & Trend Analysis4.1 Cell Therapy Market (Stem & Non-stem Cells): Use-type Movement Analysis4.2 Clinical-use4.3 Research-use

Chapter 5 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Therapy Type Estimates & Trend Analysis5.1 Cell Therapy Market (Stem & Non-stem Cells): Therapy Type Movement Analysis5.2 Allogeneic Therapies5.3 Autologous Therapies

Chapter 6 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Regional Estimates & Trend Analysis, by Product6.1 Cell Therapy Market (Stem & Non-stem Cells) Share by Regional, 2019 & 20276.2 North America6.3 Europe6.4 Asia-Pacific6.5 Latin America6.6 MEA

Chapter 7 Competitive Landscape7.1 Strategy Framework7.2 Company Profiles7.2.1 Kolon TissueGene, Inc.7.2.2 JCR Pharmaceuticals Co. Ltd.7.2.3 MEDIPOST7.2.4 Osiris Therapeutics, Inc.7.2.5 Stemedica Cell Technologies, Inc.7.2.6 Cells for Cells7.2.7 NuVasive, Inc.7.2.8 Fibrocell Science, Inc.7.2.9 Vericel Corporation7.2.10 Pharmicell Co. Ltd.7.2.11 Anterogen Co. Ltd.7.2.12 Celgene Corporation

For more information about this report visit https://www.researchandmarkets.com/r/5bjbpt

Story continues

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See original here:
Global Cell Therapy (Autologous, Allogeneic) Markets to 2027 - Yahoo Finance